EPISODE · Jan 26, 2026 · 31 MIN
Tirzepatide (GIP/GLP-1 Agonists) for Diabetes: Pharmacology Made Easy
from This Is Why with Dr. Busti · host Anthony Busti, MD, PharmD, MSc, FNLA, FAHA
Tirzepatide (Mounjaro/Zepbound)—the dual incretin GIP/GLP-1 agonist—is a beneficial treatment of type 2 diabetes and/or obesity. In this lecture from This is Why, Dr. Busti will break down how tirzepatide works (MOA), why combining GIP + GLP-1 improves A1C reduction and supports weight loss, and where it fits in the treatment of type 2 diabetes. You’ll also get the high-yield points you need for exams and the bedside: tirzepatide dosing basics, common adverse effects, contraindications/precautions, and practical tips for patient counseling (nausea, GI effects, injection technique, and expectations).You’ll learn how to:- Tirzepatide overview: Mounjaro vs Zepbound- GIP/GLP-1 agonist mechanism (dual incretin)- Clinical use in type 2 diabetes- A1C lowering + weight loss effects- Adverse effects, warnings, and counseling pearlsThe goal = make medical education easy and clinically relevant.👉 Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/tirzepatide-mounjaro-zepbound-gip-glp1-agonist-type-2-diabetes-pharmacology👉 Get more with a free membership at https://www.thisiswhy.health/- Access free downloads from our videos - Access deep dive content from Dr. Busti- Organize content via playlists & collections- Join live Q&A- Receive member newsletters- Coupons & discounts for exam prep resources👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!#tirzepatide #mounjaro #gipglp1 #type2diabetes #bustiDisclaimer:This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.
Embed this episode
What this episode covers
Tirzepatide (Mounjaro/Zepbound)—the dual incretin GIP/GLP-1 agonist—is a beneficial treatment of type 2 diabetes and/or obesity. In this lecture from This is Why, Dr. Busti will break down how tirzepatide works (MOA), why combining GIP + GLP-1 improves A1C reduction and supports weight loss, and where it fits in the treatment of type 2 diabetes. You’ll also get the high-yield points you need for exams and the bedside: tirzepatide dosing basics, common adverse effects, contraindications/...
NOW PLAYING
Tirzepatide (GIP/GLP-1 Agonists) for Diabetes: Pharmacology Made Easy
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.